Maresyl Comb (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline hydrochloride is an alpha‑adrenergic agonist. By stimulating alpha receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and edema. This narrowing of vessels decreases the volume of tissue in the nasal passages, leading to rapid decongestion.

The specific dosing regimen for Maresyl Comb is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Typically, the prescriber will advise the number of sprays per nostril and the maximum duration of treatment.

Safety data for Maresyl Comb in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this nasal spray.

To request Maresyl Comb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maresyl Comb combines a vasoconstrictor (xylometazoline) with an anticholinergic (ipratropium), offering both reduction of mucosal swelling and decreased secretions. Single‑agent decongestants lack the anticholinergic component, so Maresyl Comb may provide broader symptom control, especially for runny nose, while still sharing similar cautions about short‑term use.

Store Maresyl Comb at room temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product if the container is damaged or the solution appears discolored.

Maresyl Comb is administered as a nasal spray. The user gently inserts the tip into one nostril, closes the opposite nostril, and sprays the prescribed number of actuations while breathing in gently. The same procedure is repeated for the other nostril if directed by the prescriber.

Serious risks, though uncommon, include severe nasal ulceration, allergic reactions such as rash or anaphylaxis, rebound congestion (rhinitis medicamentosa) after prolonged use, and elevated intra‑ocular pressure. Patients should seek immediate medical attention if they experience intense pain, swelling, or signs of an allergic reaction.

Maresyl Comb should be avoided in children younger than 6 years, in patients with known hypersensitivity to xylometazoline, ipratropium, or any excipients, and in individuals who have had recent nasal surgery or trauma unless cleared by a clinician. It is also contraindicated in patients taking MAO inhibitors.